Biotechnology News and Research

RSS

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Drug delivery company pSivida Corp today announced it amended and restated its Research and Development Agreement with Pfizer Inc. to focus solely on the development of a long-term, sustained-release implant to deliver latanoprost for patients with ocular hypertension and glaucoma.

15 Jun 2011

Akela reports total consolidated revenues of $4.2 million for three months ended March 31, 2011

Akela Pharma, Inc., a drug development company with its lead product, Fentanyl TAIFUN, being developed for the treatment of breakthrough cancer pain and the company's wholly owned subsidiary, PharmaForm, a leading specialty contract service provider in the area of pharmaceutical dosage form development and manufacturing, today announced its financial results for the three months and year ended March 31, 2011.

15 Jun 2011

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.

15 Jun 2011

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes.

14 Jun 2011

Enox to receive European patent for 'Device and Method for Administering Therapeutic Agents'

Enox Biopharma, Inc., a leader in the development of innovative solutions for infections associated with medical devices, today announced that it has received notification from the European Patent Office that its patent application entitled "Device and Method for Administering Therapeutic Agents" has been approved and a patent will be granted.

14 Jun 2011

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

Fox Chase Cancer Center, one of the nation's leading cancer research and treatment institutions, today announced it has entered into an agreement with Life Technologies Corporation that will underpin a new program to provide next-generation sequencing analysis of solid tumors.

14 Jun 2011

Milestone completes $13 million round of equity financing

Milestone Pharmaceuticals Inc., a cardiovascular drug development company, announces the completion of a $13 million round of equity financing.

13 Jun 2011

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Alexion Pharmaceuticals, Inc. today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes.

13 Jun 2011

inVentiv Health acquires i3 CRO

inVentiv Health, Inc., offering best-in-class clinical, consulting and commercial services to the healthcare industry, today announced it has completed the acquisition of i3, a top-tier contract research organization (CRO) to the pharmaceutical, biotech and medical device industries. i3 was previously owned by Ingenix, a UnitedHealth Group company.

13 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical trial showing that patients who received four doses of its ToleroMune cat allergy vaccine over a 12-week period maintained a statistically significant reduction in symptoms one year later.

13 Jun 2011

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

Kareus Therapeutics SA, the company focused on the development of novel therapeutics to address high unmet medical need, today announced a broad strategic alliance with Quintiles to progress the development of two of Kareus' pre-clinical programs through clinical trials.

13 Jun 2011

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

Hundreds of surfers, cancer survivors and friends will gather together, with surfboards in hand, on La Jolla Shores Sunday, June 19 for an annual San Diego tradition: Survivor Beach. Attendees will place surfboards along the edge of the shore, nose-to-tail, from Scripps Pier down La Jolla Shores, with the goal of forming a record-breaking line of several hundred surfboards.

13 Jun 2011

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc., announced today that data on ADCETRIS (brentuximab vedotin) in relapsed or refractory Hodgkin lymphoma patients were featured in an oral presentation at the 16th Congress of the European Hematology Association (EHA) in London.

13 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

Larger trial study needed to decide fate of niacin

Niaspan is a cholesterol drug manufactured by Abbott Laboratories. Doctors have customarily prescribed Niacin to raise levels of HDL ("good" cholesterol) in patients taking a statin pill that is successfully lowering their LDL ("bad" cholesterol).

10 Jun 2011

Revance closes $45 million financing

Revance Therapeutics, Inc. today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures and new investor, NovaQuest Capital.

10 Jun 2011

Life Technologies enters exclusive agreement for TAL Effector Technology license

Life Technologies Corporation has signed an exclusive license agreement for novel technology that enables synthetic biologists to effectively program and control the genetic circuitry in engineered pathways and organisms.

10 Jun 2011

Patheon second quarter revenues decrease 3.1% to $170.0 million

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today financial results for the second quarter ended April 30, 2011.

10 Jun 2011

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet's blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.

10 Jun 2011

Biotechnology News and Research

Pfizer, pSivida partner to develop latanoprost implant for ocular hypertension and glaucoma

Akela reports total consolidated revenues of $4.2 million for three months ended March 31, 2011

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

Enox to receive European patent for 'Device and Method for Administering Therapeutic Agents'

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

Milestone completes $13 million round of equity financing

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

inVentiv Health acquires i3 CRO

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

Cancer survivors and friends to attend San Diego's Survivor Beach event on June 19

Seattle Genetics, Millennium ADCETRIS phase I trial data on Hodgkin lymphoma presented at EHA

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Larger trial study needed to decide fate of niacin

Revance closes $45 million financing

Life Technologies enters exclusive agreement for TAL Effector Technology license

Patheon second quarter revenues decrease 3.1% to $170.0 million

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News